Clinical Trials

The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be ...

The purpose of this study is to develop urine tests that will measure biological markers and use them to track the status of kidney disease. This test may help doctors to better care for patients with kidney disease.

This study is being done to create a "resource" of samples that can be used to improve our ability to diagnose and treat MN, IgAN, MPGN, FSGS/MCD, Lupus Nephritis, AAV, other glomerular tubulo-interstitial disease.

The purpose of this registry is to establish a database of patients diagnosed with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or immunoglobulin A nephropathy (IgAN), to advance the diagnosis and care of patients with glomerular diseases.

The purpose of this research study is to learn more about the risks to heart health in children and young adults with nephrotic syndrome. Nephrotic syndrome is a rare kidney condition that can affect children. They may be more likely to develop heart disease, high blood pressure and high cholesterol. We hope that the results of this study will help us to learn which tests should be used to determine which patients are most at risk for developing these illnesses.